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Abstract
Patients infected with HIV exhibit orders of magnitude differences in their set-point levels of the plasma viral load. As to
what extent this variation is due to differences in the efficacy of the cytotoxic T lymphocyte (CTL) response in these patients
is unclear. Several studies have shown that HIV-infected CD4
+ T cells also present viral epitopes that are recognized by CTLs
before the productive stage of infection, i.e., during the intracellular eclipse phase before the infected cell starts to produce
new viral particles. Here, we use mathematical modeling to investigate the potential impact of early killing of HIV-infected
cells on viral replication. We suggest that the majority of CTL-mediated killing could occur during the viral eclipse phase,
and that the killing of virus-producing cells could be substantially lower at later stages due to MHC-I-down-regulation. Such
a mechanism is in agreement with several experimental observations that include CD8
+ T cell depletion and antiretroviral
drug treatment. This indicates a potentially important role of CTL-mediated killing during the non-productive stage of HIV-
infected cells.
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Introduction
Infection with HIV typically leads to a vast replication of the
virus during the acute phase of the infection which is followed by a
chronic phase where the viral load approaches a quasi-steady-
state, known as the viral set-point. It has been shown that the viral
load levels can vary over orders of magnitude between patients [1–
3] and the set-point level has been recognized to be an important
predictor for disease progression [4]. Part of the difference in the
control of HIV replication between patients has been attributed to
varying efficacies of the patient’s immune responses to induce
cytotoxic T lymphocyte (CTL)-mediated killing of infected cells
[5–8]. A major role of the CD8z T cell response in controlling
HIV infection is further supported by the very rapid evolution of
immune escape variants during the first months of infection [9–
11]. However, it is remarkable that the virus load declines at very
similar rates in different patients when they are treated with
antiretroviral drugs [12,13]. The viral load decay during
antiretroviral therapy is typically related to the loss of HIV-
infected cells and occurs at a rate between 0.5 and 1.5 per day
[14]. Recent experiments with depleting CD8z T cells by
antibodies have further indicated that the rate at which virus-
producing cells are cleared during antiretroviral therapy is
unaffected by the presence or absence of CD8z T cells [15,16].
Therefore, it is puzzling how CTLs could account for large
differences in the viral set-point causing a controversy as to
whether CTLs mediate control of HIV through cytotoxic or non-
cytotoxic mechanisms [17–19].
Klenerman et al. [20] have presented a mathematical model to
show that CTLs can markedly reduce the virus load by limiting
virus production with minor effects on the half-life of infected cells.
Assuming that the rate at which an infected cell becomes a target
for CTLs is slow (e.g. 0.4 d{1), it will be this transition rate rather
than the death rate of the cells that is reflected in the viral load
decline [20]. Others have adopted this model in combination with
experiments to highlight the impact of epitope expression kinetics
on the recognition of HIV-infected cells by CTLs [21,22]. Newer
studies, however, have shown that HIV-infected cells become a
target for CTLs as soon as 2 to 6 hours after infection [23–25]. It
was further shown that SIV-specific CD4z T cells recognize and
inhibit viral replication very early after infection of a cell [26]. This
suggests that the transition rate at which cells become recognized
and turn into a target for CTLs is very fast (4 to 12 d{1), and is
much higher than the typical decline rate of viral load after drug
treatment. This observation casts doubt on the explanation of
Klenerman et al. [20], and highlights two important new features.
First, that infected cells become a target for CTL-mediated killing
very early, and second, that infected cells can be killed during the
non-productive stage of infection, i.e., during the intracellular
eclipse phase.
Interestingly, HIV evolved a mechanism to partially evade
killing by CTLs through down-regulation of MHC-I molecules in
infected cells [27–29]. Down-regulation is induced by the protein
Nef [30] and starts as early as 12 h post-infection [24]. The
intracellular eclipse phase lasts around 24 hours [31–33]. Hence,
CTL-mediated killing of infected cells during the eclipse phase can
be more efficient because MHC-I is not yet down-regulated. CTLs
recognizing epitopes that are presented very early, such as epitopes
derived from the viral protein Gag, might thus mediate efficient
cytotoxic killing soon after the cell has become infected. In
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MHC down-regulation, are expected to be killed by CTLs, natural
killer (NK) cells, and the cytopathic effects of viral production,
which in combination would have to account for the typical death
rate of infected cells (0.5–1.5 d{1) that is observed after the start of
drug therapy. The fact that the death rate of infected cells that are
actively producing SIV is hardly decreased when CD8z CTL and
NK cells are depleted [15,16], seems to suggest that this typical
death rate is largely determined by the cytopathic effects of viral
production.
We devise a mathematical model of HIV dynamics to
investigate the impact of CTL-mediated killing of HIV-infected
cells during the intracellular eclipse phase. Our model can
account for large variations in viral set-point levels without
affecting the typical decay rate of virus load after drug treatment.
We further test the consistency of the hypothesis that HIV-
infected cells are cleared during the non-productive stage of
infection with several experimental observations such as the
unexpected effects of CD8z depletion experiments during
antiretroviral therapy [15,16]. While non-cytotoxic mechanisms
of CD8z T cells cannot be ruled out, our study indicates a
potentially important role of cytotoxic killing of HIV-infected
cells during the intracellular eclipse phase.
Results
Early vs. late killing of HIV-infected cells
Our model considers two types of cells infected with HIV.
Infected cells during the viral eclipse phase, I, do not produce
virus yet, whereas cells that pass the eclipse phase (caused by an
intracellular delay of virion production) become productively
infected cells, P, and release new viral particles (Fig. 1, top). Both
populations experience cell death, at a rate dI and dP respectively,
that can at least partly be due to CTL-mediated killing (see Methods
for the mathematical description).
First, we analyze which parameter regimes realistically describe
the characteristic early down slope of d^1 d{1 of the viral load
decay during effective antiretroviral treatment [12–14]. All
parameter combinations in the area between dashed lines in
Fig. 2 would account for a realistic downslope of 0:5vdv1:5 d{1
(see Methods for how these lines are computed). The influence of
the death rates of infected cells, dI, and virus-producing cells, dP,
on the reduction of the viral set-point is indicated by the contour
lines in Fig. 2. One realistic possibility to reduce the viral load
significantly is that virus producing cells die rapidly, i.e. dP is high,
while cells in the viral eclipse phase die slowly, i.e. have a low dI,
and have an eclipse phase of approximately one day (c~1 d{1).
This is depicted by region B in Fig. 2, and corresponds to the
regime previously described by Klenerman et al. [20]. In this
regime the decline slope after drug treatment is reflecting the rate
at which cells move through the eclipse phase (i.e., d^c in the
model from Eq. 1). Our main result is the new regime depicted by
region A in Fig. 2 with early killing of infected cells during the
intracellular eclipse phase, i.e., high dI. This falls in the realistic
area when the death rate of producing cells would indeed
correspond to the observed downslope of the viral load during
treatment (i.e., d^dP). The length of the eclipse phase is hardly
reflected in the downslope d in the ‘early killing’ regime. Note that
there is no realistic regime where both early and late killing could
be fast. The new evidence for early killing [23–25] provides
support for the new regime depicted by region A in Fig. 2. In this
paper we investigate the implications of killing mediated early
during the intracellular eclipse as the main mechanism at which
HIV-infected cells are controlled by CTLs.
Set-point viral load
To explicitly analyze the effect of early CTL-mediated killing of
HIV-infected cells on the set-point viral load, we describe the
death rate of infected cells as dI~dTzk, which sums the natural
death rate of CD4z cells, dT, with a function describing CTL-
mediated killing, k. The death rate of virus-producing cells, dP,
remains small and constant and is a combination of natural death,
virus induced cytotoxicity, moderate CTL-mediated killing, and
killing by NK cells as a consequence of MHC-I down-regulation.
First, consider the simple case with a constant CTL response,
i.e. k~k, where the death rate during the eclipse phase,
dI~dTzk, is a constant like in Fig. 2. Here the total CTL
response kills infected cells, I, at a rate k per day. Increasing k
reduces the set-point viral load (Fig. 3A), and increasing the rate of
killing above a threshold of k&5 d{1 will clear the infection. The
basic reproductive number (R0) indeed falls below 1 at the same
critical value of k (Fig. 3C, see Methods for the definition of R0).
Early killing can therefore be extremely efficient, and could in
theory clear the infection if infected cells during the eclipse phase
are expected to be killed at a rate exceeding a value of
Figure 1. MHC-I density and epitope presentation on the
surface of an HIV-infected cell. On top, an infected cell, I, is shown
that passes through the eclipse phase to become a virus-producing cell,
P. In the middle panel, the relative MHC-I density is shown as being
down-regulated around 12 h after infection. The bottom panel depicts
the early surface presentation of epitopes during the first 24 hours after
infection. Gag and Pol epitopes show a peak shortly after infection since
they are derived from the infecting virus particles. Later, de novo
synthesis of viral proteins takes place, generating the early proteins Tat,
Rev and Nef and the late proteins Env, Gag and Pol. The viral eclipse
phase is denoted by the white area. After the eclipse phase, virus-
producing cells, P, are likely to experience a moderate death rate due to
the MHC-I-down-regulation (gray area). The illustrations are based on
kinetic data from Sacha et al. [23,24].
doi:10.1371/journal.pone.0016468.g001
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five hours after infection.
Second, consider CTL effector cells E that proliferate according
to a function r and die at a rate dE per day. These CTLs kill
infected cells, I, according to a specific function k. For the detailed
mathematical description of the CTL proliferation r and the
CTL-mediated killing k, we refer to Methods. To account for
different efficacies of CTL-mediated killing we can change the
saturation parameter of the killing term, hk, in this function. hk is a
generalized Michaelis-Menten constant, and decreasing hk
increases the killing rate of cells expressing ‘early’ epitopes. This
allows us to have a single parameter defining the ‘immune
responsiveness’, which turns out to account for orders of
magnitude differences in viral load set-point levels (Fig. 3B). The
corresponding R0 now approaches 1 when hk is reduced, i.e., the
efficacy of CTL-mediated killing is increased to k&5 d{1
(Fig. 3D).
This analysis demonstrates that ‘early killing’ is an efficient
control mechanism, i.e., can account for large variations in the
viral load between patients by substantial differences in the efficacy
of the immune response, and for a critical killing rate at which the
infection is cleared. However, it does not imply that early killing is
more efficient than late killing, or that the critical killing rate of
approximately 5 d{1 is a reliable estimate. First, the killing rate at
which the infection is cleared does depend on other parameters
(not shown). But tuning the other parameter values such that we
obtain a realistic viral replication rate of 1.5 d{1 during the acute
phase of infection (see Table 1) results in critical killing rate that is
at least plausible. Second, one can also repeat the bifurcation
analysis of Fig. 3 for different assumptions on the distribution of
the killing over the early and the late stages of an infected cell. One
possibility is that most killing occurs late, which we can study by
letting dI~dT and dP~dTzk. This yields a very similar critical
rate of about 5.5 d{1 (not shown). Late killing is therefore an
equally efficient control mechanism, and would be consistent with
the characteristic early down slope of d^1 d{1 of the viral load
decay during effective antiretroviral treatment [12–14] when there
is little early killing, and an eclipse phase of approximately one day
(see region B in Fig. 2) [20]. Alternatively, the killing rates during
the early and late phases could be assumed to be similar, e.g., by
setting dP~dI~dTzk. This results in a lower but still relatively
high threshold killing rate of approximately 2 d{1 (not shown).
Killing that is mediated during the early and late stage of an
infected cell is therefore also an efficient control mechanism but
would require a viral load decay during antiretroviral treatment
that is not consistent with the characteristic down slope of d^1
d{1 [12–14].
Summarizing, we have shown that if CTL-mediated killing
happens before the infected cell starts to produce new viral
particles, the viral load can be suppressed very effectively by the
CTL response, independent of the predicted downslope of the
viral load during drug treatment. The infection can be cleared
when the killing rate during the eclipse phase exceeds a rate of 5
per day. Such a high killing rate has never been consistent with the
viral load decay data, and has therefore has not been considered in
studies of the effect of CTL on controlling HIV-1 infection [34].
Reproducing experimental observations of HIV dynamics
Viral load decay during drug treatment. We demon-
strated above that ‘early killing’ can account for large differences
in viral set-point levels while the observed death rate of virus-
producing cells during antiretroviral therapy would remain largely
invariant. This characteristic behavior is depicted by the solid lines
in Fig. 4A, where the set-point viral load varies over orders of
magnitude when the saturation constant of the immune response is
changed, but decreases with the same rate after starting therapy.
Recent experiments combining drug treatment with CD8z T cell
depletion also suggested that CTL-mediated killing is not
responsible for the death of virus-producing cells. In SIV-infected
rhesus macaques, the viral load decay following the administration
of antiretroviral drugs was not different in CD8z T depleted
animals compared to controls [15,16]. In our model we can
reproduce this observation by performing an in silico experiment
where CD8z depletion takes place at the same time when drug
treatmentisstarted.Technicallyspeaking,wesetthe infectionrateb
to zero and the number of CTL effector cells to low levels at the
onset of treatment. Because in our ‘early killing’ regime the death
rate of virus producing cells hardly depends on the CTL response,
we obtain the same exponential decay of the viral load as observed
when CTL are not removed (dashed lines in Fig. 4A). Interestingly,
the shoulder phase after the start of treatment, that is typically
assumed to be caused by the intracellular delay, becomes longer
when CD8z depletion is performed. This is due to the fact that a
larger fraction of the cells in the eclipse phase at the start of
treatment will move into the state of virus-producing cells when
CTLs are removed.
Early CD8z depletion experiments. Strong evidence
that CTLs are responsible in suppressing the viral load during
Figure 2. Influence of early and late death rates of HIV-infected
cells on the viral load and the slope of the virus decline after
drug treatment. During the viral eclipse phase, infected cells, I,
experience a death rate of dI per day whereas virus-producing cells, P,
die at a rate dP. The contour lines depict the impact of cell death on
reducing the viral load (see Methods). The area where the virus decline
slope is between 0.5 d{1 and 1.5 d{1 is given by the dashed lines.
Region A: Infected cells experience a higher death rate during the
eclipse phase than later when they start to produce new viral particles.
Hence, the slope of the virus decline after drug treatment is determined
by dP. Region B: As the death rate of infected cells during the eclipse
phase is low, the decline slope after drug treatment is determined by
the rate at which cells move through the eclipse phase (c~1:0 d{1).
The exponential slope of the virus decline is calculated at 5 days after
the start of treatment. For the mathematical derivation we refer to
Methods.
doi:10.1371/journal.pone.0016468.g002
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PLoS ONE | www.plosone.org 3 February 2011 | Volume 6 | Issue 2 | e16468Figure 3. Set-point viral load and the basic reproductive number, R0, as a function of CTL-mediated killing. The left panels depict the
behavior when killing is induced with a total rate k per day. The viral load decreases sharply for k&5 d{1 (A) since R0 falls below one, and the
infection is cleared (C). If CTL effector cells form a complex with the infected cell before delivering their lethal hit, we assume a maximal killing rate
(kmax~50 d{1) and change the Michaelis-Menten constant hk instead. This way, we can account for orders of magnitude differences in the viral load
(B) since R0 is slowly approaching one (solid line, D). The total killing (dashed line, D) induced by all CTL effector cells is approaching the same critical
value around 5 d{1 although kmax~50 d{1. In panel (A) and (B), the dotted line represents the usual detection limit for HIV-1. The dotted line in
panel (C) and (D) depicts the R0 of 1 below which the infection cannot sustain itself anymore.
doi:10.1371/journal.pone.0016468.g003
Table 1. List of parameter values for the HIV dynamics model.
Parameter Value Explanation and reference
l 2|105 cells d{1 Tuned to obtain a maximal viral load around 107 per ml
in the absence of a CTL response.
dT 0:1 d{1 Natural death rate of CD4z target cells T.
b 3|10{8 d{1 Infection rate per virus particle. Results in a maximal
viral replication rate of 1:5 d{1 [61].
c 1:0 d{1 Viral eclipse phase of 24 hours [31,32].
dI 0:1 d{1 Natural death rate of infected cells I.
dP 1:0 d{1 Death rate of virus-producing cells [31,32].
p 2300 d{1 Virus production rate.
dV 23 d{1 Clearance rate of viral particles [56].
kmax 50 d{1 Maximal killing rate [62].
hk ½1,109  cells Variable efficacy of CTL response.
g 1:5 d{1 Maximal CTL proliferation rate of 1.0 d{1 [63].
hg 0 cells CTLs are stimulated to proliferate rapidly.
dE 0:5 d{1 Death rate of CTL effector cells.
doi:10.1371/journal.pone.0016468.t001
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load after CD8z T cell depletion. Monkeys infected with simian
immunodeficiency virus (SIV) show a rapid and transient increase
in their viral load over orders of magnitude upon depleting their
CD8z T cells [6,35,36]. This observation was difficult to explain
with a mathematical model [35] in which the CD8z T cell
depletion affects the death rate of virus-producing cells. Jin et al.
[35] also investigated non-cytotoxic mechanisms, such as
increasing virus production or increasing infection rates, but
concluded that the model fails to accurately describe the
experiments. Later, it was suggested that an ‘early cytotoxic’
immune response could eliminate infected cells before they
produce viral particles, and such a model readily explained the
large and rapid increase in the viral load in the CD8z T cell
depletion experiments [2]. Similarly, with our model that explicitly
takes into account a CTL response targeting infected cells during
the intracellular eclipse phase, we can account for a strong
suppression of virus replication during the chronic phase of
infection. Upon CD8z T cell depletion, the number of cells
becoming virus-producing cells increases rapidly leading to a
transient increase in the viral load (Fig. 4B). We obtain similar
peak viral loads for the different set-point levels because in the
absence of an immune response, the viral load in our model is
expected to approach the steady-state determined by limited target
cell availability, which is independent of the hk parameter. These
similar levels are not in agreement with the variation in peak viral
loads in the study of Jin et al. [35], which could be due to the
differences in target cell availability in the CD8z T cell depleted
monkeys, and/or due to different efficacies of CD8z T cell
depletion in the monkeys. After the peak, the viral load reaches the
previous set-point since the CD8z T cells start to proliferate again
(Fig. 4C). Thus, the rapid and dramatic effects of CD8z T cell
depletion are perfectly consistent with cytotoxic control of viral
replication, if – and only if – this control occurs early in the life
cycle of an infected cell.
Discussion
The traditional concept of recognition of HIV-infected cells by
CTLs was that the cells have to express viral proteins first before
they can present viral epitopes on their surface. This belief implied
a puzzling problem because specific CD8z T cell responses
appear to be strongly associated with different viral set-point levels
in patients [3,37], but the death rate of virus-producing cells is very
similar in different patients [14]. The notion that the death rate of
virus-producing cells is largely unaffected by the CTL response
was further supported by the similar decay kinetics of the viral load
in treated natural hosts of SIV, i.e., sooty mangabeys and African
green monkeys, that experience little immune activation and
trigger weak CTL responses [38,39]. This problem raised
questions about the role that CTL play in controlling HIV-1
infection. In this paper we have shown that these seemingly
contradictory findings become perfectly consistent when most of
the CTL-mediated killing of HIV-infected cells occurs during the
viral eclipse phase, i.e., during the intracellular delay before the
infected cell starts to produce new viral particles. During the viral
eclipse phase, HIV-infected cells can be recognized by epitopes
derived from the proteins that enter the cell with a viral particle
[23–26].
Another observation that caused controvery on the role of CTL
in controlling HIV-1 infection was the absence of an effect of
depleting CD8z T cells on the death rate of virus-producing cells
[15,16]. One interpretation of these experiments was that specific
CD8z T cells largely exert non-cytotoxic effects (while it was also
stated that the possibility of CTL-mediated killing during the non-
productive stage of infection cannot be ruled out). We have shown
that cytotoxicity during the eclipse phase is indeed perfectly
consistent with the absence of an affect of CD8z T cell depletion
during antiretroviral treatment. An experiment to test whether
Figure 4. Reproducing experimental observations of HIV
dynamics. A) After drug treatment, the viral load declines proportion-
ally to the number of virus-producing cells (straight lines). Since the
death rate of these cells, dP, is constant, we observe the same slope for
the exponential decay of viral load although different patients have
varying efficacies of their CTL response. Hence, the dynamics is not
affected by the killing efficacy hk which determines the set-point level
of viral load before treatment. If CTLs were depleted at the start of drug
treatment, the same phenomenon would be observed. The virus load
declines exponentially with the death rate of virus-producing cells that
is unaffected by CTL-mediated killing (dashed lines). B) In CD8z
depletion experiments, the viral load increases over orders of
magnitude, peaks around two weeks after depletion, reduces again,
and stabilizes afterwards at the previous set-point level. C) The CTLs are
depleted and start to proliferate thereafter. Black lines denote different
hypothetical patients with varying efficacies of their CTL response. Lines
from top to bottom: hk~108, hk~105, hk~5|103 and hk~102. After
CD8z depletion, the concentration of CTL effector cells is set to
E~10{4. The dotted lines represent the usual detection limit for HIV-1.
doi:10.1371/journal.pone.0016468.g004
CTL-Mediated Killing of HIV-Infected Cells
PLoS ONE | www.plosone.org 5 February 2011 | Volume 6 | Issue 2 | e16468CTL-mediated killing acts during the intracellular eclipse phase
would be to follow the dynamics of different cell populations after
drug treatment. The virus-producing cells are expected to decline
with the same rate as the viral load. In contrast, we hypothesize
that infected cells during the early stage before MHC-I-down-
regulation experience strong CTL-mediated killing, and therefore
should decay with a faster rate than the viral load.
The intriguing implication of the studies from Sacha et al. [23–
26] is that they provide an explanation why CTL responses
targeting epitopes from the protein Gag are more efficient in
controlling the viral replication than CTL responses targeting
epitopes from other viral proteins [3,40]. Since Gag epitopes are
presented on the infected cells surface early after infection, the
CTLs have a time-window of about ten hours to recognize
infected cells before their MHC-I is down-regulated. Although Pol,
Vpr and Rev epitopes are presented early as well, responses
targeting those epitopes seem to be less efficient in controlling the
viral replication. It has been argued that the number of proteins in
a virion that enter the cell leads to a different concentration of
protein-derived epitopes on the cell surface. While Gag proteins
are highly abundant, with a copy number of *5000 per virion
[41], Pol, Vpr and Rev proteins are present at much lower copy
numbers. Further, structural constraints in the protein Gag make
it more difficult for the virus to accumulate epitope escape
mutations in order to evade the CTL responses [40]. This could
explain why the rapid escape of HIV during the acute phase of
infection also occurs in epitopes derived from other proteins such
as Tat and Vif [10,11]. Because at least some of these epitopes are
not expressed during the viral eclipse phase [25], specific CD8z T
cells also seem to play an important role during the later
productive stage of an infected cell (at least during the acute
phase of infection). Whether or not this occurs mainly through late
killing in combination with a slow eclipse phase [20], or is largely
due to non-cytolytic effects during the late productive phase of an
infected cell [2,15–19,42], remains to be established.
Nevertheless, the studies by Sacha et al. [23–26] are in conflict
with previous findings on the impact of epitope expression kinetics
on the efficacy of CTL responses [43]. It has been argued before
that since Gag is a ‘late’ protein that is expressed at the end of the
viral eclipse phase, CTL responses against ‘early’ proteins such as
Rev should be more effective in the control of the viral replication.
Indeed, it was shown with recombinant viruses that RT- and Gag-
specific CTL responses become much more effective in the control
of virus replication if the epitopes are expressed as part of an early
protein, such as Rev or Nef [21,44]. This is in contrast to the
studies by Sacha et al. [23–26] where epitopes from Gag, Pol and
Rev were all presented early after infection at about the same time,
suggesting that the efficacy of those CTL responses should not
strictly correlate with the de novo protein expression kinetics. One
possible explanation for this apparent discrepancy comes from the
observation that not all epitopes from a specific protein are
presented with the same kinetics, i.e., epitopes derived from the
same viral protein experience differential antigen presentation
kinetics [45]. Indeed, different epitopes were used in these studies
[21,23,24,44], which might explain the different results of their
experiments. The antigen presentation kinetics of epitopes could
be influenced by different cleavage efficacies of the peptides by the
proteasome. Early after infection of a cell, the peptides are most
likely to be cleaved by the constitutive proteasome. At a later stage,
the immunoproteasome is expected to become expressed, which
has a different specificity [46]. Analysis of the cleavage scores
obtained by the epitope predictor NetChop [47,48] did not result
in a clearly distinct cleavage pattern between the epitopes that
have been investigated in the studies referenced above (results not
shown). In addition, the studies also used different assays to
investigate the impact of the CTL response. In Sacha et al. [23–
25], the elimination of p27 positive cells was followed during a
single infection cycle of SIVmac239, whereas the earlier studies
measured after several generations of HIV-1 infection the relative
amount of p24 antigen that was suppressed by adding specific
CTLs [21,44]. Finally, the epitope presentation kinetics is only one
of a magnitude of factors that determine the efficacy of CTLs [49].
Lastly, it needs to be investigated how efficient an HIV-infected
cell can escape recognition by CTLs through down-regulation of
MHC-I [50]. While the viral protein Nef can down-modulate
HLA-A and HLA-B, the surface presentation of HLA-C is hardly
affected. It has been speculated that this might be a strategy of the
virus to escape the most efficient CTL responses, which are
directed against epitopes presented on HLA-A and HLA-B,
whereas the lack of down-regulation of HLA-C might prevent the
cell from NK-directed killing [51]. The striking observation of the
unchanged death rates of virus-producing cells after CD8z T cell
depletion indeed challenges the view that CTL-mediated killing is
effective during the late, productive stage of the cell [15,16]. Here
we have formally demonstrated that when CTL-mediated killing
occurs early during the intracellular eclipse phase it can control
HIV replication very efficiently, while remaining consistent with
current observations on the up-slopes and down-slopes of the viral
load observed during CD8z T cell depletion experiments and
antiretroviral treatment.
Methods
HIV dynamics model
For the mathematical analysis on the influence of clearing HIV-
infected cells early or late during their viral life cycle, we devise a
model of HIV dynamics that is based on standard models of
within-host virus dynamics [52,53]. In addition, we include an
early stage of infected cells, that accounts for the eclipse phase
during which cells do not produce virus yet [20,54,55]:
dT
dt
~l{bTV{dTT
dI
dt
~bTV{cI{dII
dP
dt
~cI{dPP
dV
dt
~pP{dVV
ð1Þ
Here, non-infected CD4z target cells T are produced at a rate
of l cells per day, die at a rate dT and can become infected by
virus particles V at a rate b per day. An infected cell I can either
move through the viral eclipse phase with rate c per day to become
a virus-producing cell P, or die at a rate dI per day. Virus-
producing cells P will die with the death rate dP. Viral particles V
are produced at a rate p per day and are cleared at a rate dV. All
parameters used for the analysis of the virus dynamics are given in
Table 1. In Results, we vary the death rate of infected cells, dI,t o
account for early CTL-mediated killing during the viral eclipse
phase. The potential effects of non-cytotoxic mechanisms
mediated by CD8z T cells are discussed below.
Influence of cell death on virus production
To investigate the influence of cell death on virus production we
calculate the expected duration of viral production by a cell that
CTL-Mediated Killing of HIV-Infected Cells
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cells, dI, will reduce the fraction of cells that become virus-
producing cells. The lifespan of virus-producing cells (1=dP)
determines the amount of virus that is produced by a single cell.
From Eq. 1, the average duration at which an infected cell will
produce viral particles can be given by
d~
c
czdI
1
dP
ð2Þ
which suggests that changing dP has a larger effect on virus
production than changing dI.
Viral load decay slopes
After the administration of antiretroviral drugs, the viral load
declines exponentially during the first week and is typically related
to the loss of virus-producing cells. Since the turnover of the virus
is a fast process [56], we can set V into a quasi-steady-state with
the virus-producing cells P [57]. After the start of treatment, we
assume that the infection rate b becomes 0 and the virus will
decline as follows:
Vt ðÞ ~
V0 dIzc ðÞ e{dPt{dPe
{ dIzc ðÞ t

dIzc{dP
ð3Þ
For any value of dI, dP and c, this allows us to calculate the
exponential slope of the virus load decline at a specific time t after
drug treatment.
CTL-mediated killing of infected cells
From the general scheme where an unbound CTL effector cell,
Eu, binds a target cell, I, to form a complex, C, that after a time
delivers cytotoxic killing and releases the effector cell, i.e.,
EuzI '
ku
kb
C {
k ?Eu, one can make the total quasi-steady-state
assumption (tQSSA), dC=dt~0, to obtain the following:
k~kC~
kmaxIE
hkzIzE
ð4Þ
where kmax~k is now the maximal killing rate, and
hk~ kuzk ðÞ =kb is a generalized Michaelis-Menten constant
[54,58,59].
Proliferation of CTL effector cells
CTL effector cells are stimulated by cells presenting viral
antigen on their surface. Similar as for the killing of an infected
cell, we can derive a general scheme where an unbound CTL
effector cell, Eu, binds an antigen-presenting cell, I, to form a
complex, C, that after a time dissociates and causes the CTL
effector cell to divide, i.e., EuzI '
gu
gb
C {
g ?2EuzI. Making the
total quasi-steady-state assumption (tQSSA), dC=dt~0, one
obtains the following:
r~gC~
gmaxIE
hgzIzE
ð5Þ
where gmax~g is now the maximal proliferation rate, and
hg~ guzg ðÞ =gb is a generalized Michaelis-Menten constant
[54,58,59].
Basic reproductive number, R0
The basic reproductive number, R0, of a viral infection within a
host is defined as the number of newly infected cells produced by
one infected cell during its lifetime, assuming all other cells are
susceptible [60]. From Eq. 1, it can be expressed as
R0~
blpg
dIdTdV gzdI ðÞ
ð6Þ
To calculate R0 as a function of CTL killing, we substitute the
death rate of infected cells during the non-productive stage of
infection with dTzk. Assuming a constant CTL response, k is
simply the killing rate k. For the case where infected cells during
the intracellular eclipse phase are killed by CTL effector cells, we
compute k at the steady-state level of a chronic infection as a
function of the saturation parameter of killing, hk.
Non-cytotoxic mechanisms of CD8z T cells
CD8z T cells can also mediate non-cytotoxic effects on HIV-
infected cells [42]. Mathematically, this can be described by a
process function f that will affect certain stages of the viral life
cycle. Similar as in Muller et al. [2], we define
f~
1
1zeE
ð7Þ
where CD8z T cells E act as non-cytotoxic effector cells with
efficacy e. If CD8z T cells reduce the number of new infections,
the process function f will reduce the infection rate b, i.e., the total
amount of new infections in Eq. 1 becomes bfTV. Non-cytotoxic
mechanisms can also render newly infected cells non-infectious.
This will affect the rate at which cells move through the eclipse
phase, when the transition rate c is affected by the process
function, i.e., is given by cf. The infected cells that do not become
virus-producing cells will instead render into target cells again with
rate c(1{f).
The effects of a model with non-cytotoxic effects of CD8z T
cells on the virus dynamics are the same as shown in Results,
except that the parameter region B in Fig. 2 is also a valid
explanation for the invariant decline slope of the virus load
during drug treatment experiments. Since infected cells are not
cleared by CTL effector cells anymore, the death rate of infected
cells dI, can be moderate and smaller than the rate at which cells
move through the eclipse phase. Hence, the decay rate of viral
load after drug treatment could in principle reflect the rate at
which cells move through the eclipse phase, c, as it has been
suggested by Klenerman et al. [20].
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